Solid Biosciences Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle
globenewswire.com
news
2022-10-17 00:00:00

- AAV-SLB101 is the capsid used in SGT-003, Solid's next-generation Duchenne gene therapy, expected to enter the clinic in late-2023 - - Additional novel capsids based on AAV-SLB101 binding protein data are also under evaluation and offer potential to improve safety and efficacy of Duchenne gene therapy - - In vitro data evaluating agents for enhancing AAV transduction in muscle cells presented in an additional poster - CHARLESTOWN, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences, a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), presented additional data characterizing AAV-SLB101, a novel adeno-associated virus (AAV) vector designed for improved transduction efficiency and biodistribution to muscle cells.
